Surgery is the standard care for patients with stage I lung cancer. Despite successful surgery, 20-30% of patients will relapse. Chemotherapy can improve patient survival; however, it is controversial if early stage cancer patients should be treated with chemotherapy since, for many cases, it will harm quality of life with little therapeutic benefit.
Utilizing patient samples, the investigators conducted a retrospective study in eight patient cohorts that validated the gene classifier set. These prognostic methods can guide physicians to select appropriate treatment and follow-up while sparing other patients of unnecessary treatment and negative side-effects of chemotherapy.
- Method to determine the prognosis of patients with lung cancer.
- Method to select more effective treatment and post-operative follow-up for patients with early stage lung cancer.
- Assays were validated in human tissue samples and eight different patient cohorts.
Curtis Harris (NCI), Aaron Schetter (NCI), Ichiro Akagi (NCI), Hirokazu Okayama (NCI)
Ichiro Akagi et al. [PMID 23639940]
- Foreign Issued: European - Patent Number 2885425, Issued 26 Jul 2017
- U.S. Patent Filed: U.S. Patent Application Number 14/423,069, Filed 20 Feb 2015